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It is well-known that heparin and other glycosaminoglycans (GAGs) inhibit complement
activation. It is however not known whether fractionation and/or modification of GAGs
might deliver pathway-specific inhibition of the complement system. Therefore, we
evaluated a library of GAGs and their derivatives for their functional pathway specific
complement inhibition, including the MASP-specific C4 deposition assay. Interaction
of human MASP-2 with heparan sulfate/heparin was evaluated by surface plasmon
resonance, ELISA and in renal tissue. In vitro pathway-specific complement assays
showed that highly sulfated GAGs inhibited all three pathways of complement. Small
heparin- and heparan sulfate-derived oligosaccharides were selective inhibitors of the
lectin pathway (LP). These small oligosaccharides showed identical inhibition of the
ficolin-3 mediated LP activation, failed to inhibit the binding of MBL to mannan,
but inhibited C4 cleavage by MASPs. Hexa- and pentasulfated tetrasaccharides
represent the smallest MASP inhibitors both in the functional LP assay as well in
the MASP-mediated C4 assay. Surface plasmon resonance showed MASP-2 binding
with heparin and heparan sulfate, revealing high Kon and Koff rates resulted in a
Kd of ∼2µM and confirmed inhibition by heparin-derived tetrasaccharide. In renal
tissue, MASP-2 partially colocalized with agrin and heparan sulfate, but not with
activated C3, suggesting docking, storage, and potential inactivation of MASP-2 by
heparan sulfate in basement membranes. Our data show that highly sulfated GAGs
mediated inhibition of all three complement pathways, whereas short heparin- and
heparan sulfate-derived oligosaccharides selectively blocked the lectin pathway via
MASP-2 inhibition. Binding of MASP-2 to immobilized heparan sulfate/heparin and partial
co-localization of agrin/heparan sulfate with MASP, but not C3b, might suggest that in
vivo heparan sulfate proteoglycans act as a docking platform for MASP-2 and possibly
prevent the lectin pathway from activation.
Keywords: lectin pathway, MASP-2, tetrasaccharide, heparin, complement, glycosaminoglycans
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INTRODUCTION
As a part of the innate immune system, complement consists
of soluble, and cell bound proteins. The complement system
is activated via three different pathways; the classical pathway
(CP), lectin pathway (LP), and alternative pathway (AP). The
CP is initiated by the binding of C1q to IgG or IgM and the
LP by pattern recognition molecules binding to carbohydrates
of pathogens or self-antigen. This leads to a conformational
change and subsequent activation of the associated serine
proteases C1r/C1s and MASP-1/MASP-2, respectively. These
serine proteases cleave C2 and C4, forming the C4bC2a complex,
a C3 convertase which deposits C3b initiating the amplification
loop. The AP can be initiated either by auto activation of C3
eventually forming the C3 convertase C3bBb, or by in situ
binding of AP stimulator properdin to the cell surface. Formation
of the C5 convertase in the end leads to the generation of the
C5b-9 membrane attack complex, resulting in cell lysis (1).
In the field of nephrology, complement has gained increased
attention in recent years as studies have identified complement
as a key player in multiple renal diseases. The classical pathway
(CP) has been shown to play a major role in the auto-
immune disease lupus erythematosus (2). In addition, lectin
pathway (LP) components, either in plasma, or deposited
within the kidney, have been correlated to disease progression
following human kidney transplantation and hemodialysis, IgA
nephropathy and diabetic nephropathy (3–6). Furthermore, it
has been shown that mannan binding lectin (MBL) and collectin-
11 recognize epitopes in I/R damaged kidneys and increase I/R
induced damage (7, 8). Finally, the alternative pathway (AP)
has been identified as a factor in the physiopathology of dense
deposit disease, C3 glomerulopathy, atypical hemolytic uremic
syndrome, and progression of proteinuric renal diseases (9–13).
Therefore, complement-targeted therapies can potentially be of
great use in a variety of renal diseases and conditions.
The in vivo inhibitory potential of heparin on the complement
system has been known for∼25 years (14). Since then, numerous
interactions have been described between glycosaminoglycans
(GAGs) such as heparin, and complement components. In the
lectin route of complement, anti-thrombin bound to heparin is
a strong inhibitor of C4 cleavage by MASPs (15). Besides the
lectin pathway, heparin can also block the classical pathway by
directly inhibiting the C1q subunit of C1 or by potentiating the
effect of C1-inhibitor (16–18). Studies by our group showed that
the binding of both properdin, an alternative pathway initiator
and stabilizer, and factor H, an alternative pathway inhibitor,
to heparan sulfates (HS) on proximal tubular epithelial cells
can be prevented by heparin and some other GAGs (12, 13).
Combined, these studies indicate that GAGs have the potential
to inhibit different components of the three pathways of the
complement system.
Proteoglycans are glycoconjugates consisting of a core protein
to which GAGs are covalently attached. Proteoglycans, such as
the members of the syndecan and the glypican families, can
be found on the cell membrane, others like versican, perlecan,
and agrin are found in the extracellular matrix. Membrane
proteoglycans function as highly abundant, relatively low affinity
co-receptors for growth factors, chemokines, and adhesion
molecules and modulate proliferation, migration, and adhesion
events (19). Matrix-associated proteoglycans mostly function as
storage depot for mediators, which can be released for paracrine
functions upon tissue remodeling by proteases, sulfatases, and/or
heparanase (20–22). GAGs consist of repetitive disaccharide
units, which can be modified enzymatically in their length and
sulfation pattern to alter their binding capacity and function. The
effects on binding capacity and pharmacokinetics of GAG length
modifications have been known for some time and have led to
the introduction of lowmolecular weight heparins.Modifications
of heparan sulfate (HS) sulfation are well-known from in vivo
modifications of proteoglycan side chains upon stimuli like
inflammation and fibrosis (23, 24). HS/Heparin can carry sulfate
groups on the N position and/or on the 3-O, 6-O, and 2-O
position of glucosamine and iduronic acid residues, respectively.
Degree of sulfation is positively correlated to the electro-
negativity of HS/Heparin and therefore to their binding capacity,
making it an important factor in various cellular functions. It
has for example been shown that the binding of heparin to anti-
thrombin III depends on a specific pentasaccharide structure,
in which 3-O sulfation is essential (25). Moreover, our group
has shown that properdin and factor H require different GAG
sulfation patterns for HS binding (13). These examples illustrate
the important role of chain length and sulfation pattern of GAGs
for specific interactions related to biological properties.
In this study, we aimed at identifying pathway-specific
complement inhibiting GAGs from a library of natural and
enzymatically and chemically modified and/or depolymerized
GAGs. We show that small heparin- and HS-derived
oligosaccharides are specific inhibitors of the LP of complement
and that these sugars inhibit the LP via inhibition of the MASP-2
enzyme. By surface plasmon resonance we confirm MASP-2 to
be a HS/heparin binding protein. Moreover, we provide some
evidence that HS proteoglycans in situmight bind and eventually
regulate MASP-2 in vivo.
MATERIALS AND METHODS
Polysaccharides
Heparin from ovine intestinal mucosa, heparin from bovine
lung, heparin (∼2.5 sulfate groups/disacch) and HS from
porcine intestinal mucosa (∼1.0 sulfate groups/disacch),
Chondroitin sulfate-A, -B, -and C, dextran T40, dextran sulfate,
fucoidan, were purchased from Sigma (Sigma, Zwijndrecht,
The Netherlands). Nadroparin (Fraxiparine R©) was purchased
from Sanofi Winthrop (Maassluis, The Netherlands), Dalteparin
(Fragmin R©) was purchased from Pharmacia & Upjohn, and
enoxaparin (Clexane R©) was purchased from Rhone-Poulenc
Rorer (Paris, France). HS isolated from bovine kidney (∼0.8
sulfate groups/disacch) or from Engelbreth-Holm-Swarm
sarcoma (∼0.6 sulfate groups/disacch) were obtained from
Seikagaku Corp (Tokyo, Japan). Escherichia coli capsular
polysaccharide K5, with the same (GlcUA→ GlcNAc)n
structure as the non-sulfated HS/heparin biosynthetic precursor
polysaccharide (0.0 sulfate groups/disacch) (26); O-sulfated K5
and low molecular weight O-sulfated K5; were kindly provided
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by Dr. G. van Dedem (Diosynth, Oss, The Netherlands),
as well as the heparin-derived octasaccharides (Org32100),
hexasaccharides (Org 32101), and tetrasaccharides (Org 32102).
HS from bovine intestine was kindly provided by Marco
Maccarana (Department of Experimental Medical Science,
Biomedical Center, University of Lund, Sweden) (27). HS from
human aorta was isolated essentially as described by Iverius (∼0.6
sulfate groups/disacch) (28).N +O-sulfated K5 was produced by
N-deacetylation (hydrazinolysis), subsequent N-sulfation with
sulfur trioxide-trimethylamine (29) of O-sulfated K5, followed
by N-acetylation. Heparin and HS-derived oligosaccharides were
prepared as previously described (30, 31) by partial heparinase I
(Grampian enzymes, Orkney, UK) depolymerization of porcine
mucosal heparin and exhaustive digestion of porcine mucosal
HS with heparinase III (Grampian enzymes). Disaccharide
analysis of SAGAG heparin tetrasaccharides was achieved by
reverse-phase ion-pair high-performance liquid chromatography
(RPIP-HPLC) as described before (32). Treatment of heparin
by the 6-O-endosulfatase HSulf-2 was performed as described
previously (33), for details on the disaccharide composition, see
(34). Enoxaparin tetrasaccharides (Ron G11237) were kindly
provided by dr. Annamaria Naggi (Ronzoni Institute, Milan,
Italy) isolated and characterized by NMR spectroscopy as
described before (35), N-desulfated, re-acetylated heparin and
periodate-oxidized and reduced heparin were also provided by
dr. Annamaria Naggi and were prepared and characterized as
described before (36). Synthetic HS tetrasaccharides were kindly
provided by prof. dr. G.J.P.H. Boons (Pharmacy, State University




The Wieslab complement assay (WieLISA) kits were obtained
from Euro Diagnostica, Malmö, Sweden. The WieLISA assay
is a straightforward ELISA-based format for the evaluation of
the three pathways of complement activation. The assays are
based on specific coatings for each pathway in combination
with specific buffer systems and measure the deposition of
the terminal C5b-9 MAC complex. The measurement of the
lectin pathway is either done by using mannan coated plates,
allowing binding of the MBL-MASP complex from serum
(in the standard WieLISA assay), or by using acetylated BSA
coated plated, allowing binding of ficolin-3-MASP complexes
from serum (in the ficolin-3 LP assay). The assays have
been described by Seelen et al. (38). Positive control serum
delivered with the kits was used as serum source for all
measurements. GAGs were diluted in route specific buffer
delivered with the kit. Final GAG concentration was 100µg/ml
in the CP and LP assay and due to a higher incubated
serum concentration 200µg/ml in the AP assay. Serum was
added to the diluted GAGs right before the plates were
incubated at 37◦C for 60min. Except for the serum (+/–
GAGs) incubation, the kit protocol was followed. Data were
expressed as % inhibition compared to the positive control.
Dose dependent assays with variable amounts of GAGs
were performed as described above. Data was presented as
representative experiments.
MBL Binding Assay
To evaluate whether GAGs could inhibit the mannan—MBL
interaction, Maxisorp immunoassay plates were incubated
overnight with 100µg/ml mannan (Sigma, Zwijndrecht, The
Netherlands) diluted in 0,1M NaCO3, pH 9,6. After washing
three times, plates were blocked with 1% BSA in PBS for
1 h. Thereafter, pooled serum diluted 1:50 in GVB++ buffer,
described by Roos et al. (39), were pre-incubated with a
concentration range of GAGs, for 15min at room temperature.
GVB++ buffer is Veronal-buffered saline (1,8mM Na-5,5-
diethylbarbital, 0,2mM 5,5-diethylbarbituric acid, 145mM
NaCl) containing 0,5mMMgCl2, 2mM CaCl2, 0,05% Tween-20
and 0,1% gelatin, pH 7.5. The pre-incubated mixture was then
incubated for 60min on the mannan coated plates at 37◦C. In
the dose dependent binding of MBL to mannan, no GAGs were
added. BoundMBL was detected with a DIG-labeled mouse anti-
human MBL antibody 1:1,000 (mAb 3e7 from Hycult Biotech,
Uden, the Netherlands) and a Sheep anti-DIG HRP labeled
conjugate 1:8,000 (Roche Diagnostics, Mannheim, Germany).
The assay was developed using tetramethylbenzidine (TMB)
(Sigma, Zwijndrecht, The Netherlands) and the reaction was
stopped with 1M H2SO4. Absorbance was measured at 450 nm
in a microplate reader. Data was expressed as % inhibition
compared to non-inhibited control. Data was presented as
representative experiment.
C4 Inhibition Assays
To evaluate whether GAGs inhibit the C4 cleavage (by C4d
deposition) by MASPs, we performed a C4 cleaving assay,
as first described by Petersen and colleagues (40). Maxisorp
immunoassay plates were incubated overnight with 100µg/ml
mannan (Sigma, Zwijndrecht, The Netherlands) diluted in 0,1M
NaCO3, pH 9,6. Thereafter, plates were blocked for 1 h using
10mM Tris-HCl, 140mM NaCl, 0,1% BSA, pH 7,4. Next, pooled
serum diluted 1:100 in 20mM Tris-HCl, 10mM CaCl2, 1M
NaCl, 0,05% Triton X-100, 0,1% BSA, pH 7,4 was incubated
overnight at 4◦C, allowing the MBL/MASP complex to bind
to mannan, but prevents MASP activation and subsequent
complement activation. Incubation of serum in 1M NaCl was
done to prevent classical pathway activation through anti-
mannan IgG3 antibodies, prevalent in the majority of the healthy
population. High ionic buffers prevent the binding of C1q to
immune complexes and disrupt the C1 complex, whereas the
carbohydrate-binding activity of MBL and the integrity of the
MBL complex are maintained under hypertonic conditions. After
washing, MBL/MASP coated plates were pre-incubated with 50
µl GAG at twice the final concentration in 10mM Tris-HCl,
140mM NaCl, 5mM CaCl2, 0,05% Tween, 0,1% BSA, pH 7,4
for 30min at 37◦C. Non-inhibited control wells were incubated
with buffer only. Without washing, 50 µl of 5µg/ml purified C4
(Hycult Biotech, Uden, the Netherlands) diluted in 10mM Tris-
HCl, 140mM NaCl, 5mM CaCl2, 0,05% Tween, 0,1% BSA, pH
7,4 was added to the pre-incubated GAGs and incubated for 1 h
at 37◦C. After washing, C4d deposition was detected using a DIG
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labeled mouse anti-human C4 antibody, diluted 1:4,000, followed
by incubation with a Sheep anti-DIG HRP labeled antibody
(Roche Diagnostics, Mannheim, Germany, dilution 1:8,000).
The assay was developed using TMB (Sigma, Zwijndrecht,
The Netherlands) and the reaction was stopped with 1M
H2SO4. Absorbance was measured at 450 nm in a microplate
reader. Data was expressed as % inhibition compared to non-
inhibited control. Experiments were independently reproduced
in triplicate.
Heparin-MBL/MASP Interaction ELISA
In three independent experiments, we tested the binding of
serum MASP-2 and recombinant MASP2 to heparin. To this
end, we coated Maxisorp immunoassay plates overnight with
5µg/ml heparin-albumin or 5µg/ml albumin diluted in PBS.
Heparin-albumin was from Sigma-Aldrich (Saint Louis, MO,
USA). According to the data sheet, this artificial proteoglycan
contained 4.8 moles heparin per mole albumin, protein content is
about 55%. After washing, plates were blocked using 1% BSA in
PBS for 1 h. Thereafter, recombinant MASP2 or pooled human
serum diluted in GVB++ buffer was incubated for 2 h at 4◦C.
Binding of MASP-2 was detected by incubating rat anti-human
MASP-2 (Hycult Biotech, Uden, theNetherlands) diluted at 1:200
in PBS, 1% BSA and 0,05% Tween. Rabbit anti-Rat HRP labeled
(DAKO, Glostrup, Denmark) diluted 1:500 in PBS, 1% BSA and
0,05% Tween was incubated for 1 h. The assay was developed
using TMB (Sigma, Zwijndrecht, The Netherlands), the reaction
was stopped with 1M H2SO4. Absorbance was measured at
450 nm in a microplate reader.
Surface Plasmon Resonance Analysis
To define the binding affinity of MASP-2 to heparin derivatives
surface plasmon resonance (SPR) experiments were performed
using recombinant human MASP-2 protein containing the
catalytic fragment (CCP1-CCP2-SP), which was prepared as
described earlier (41). All experiments were performed on a
BIAcore T200 (GE healthcare), using as previously described
standard procedures and GAG biotinylation techniques (40).
Briefly, reducing-end biotinylated 6 and 15 kDa heparin, and HS
(porcine mucosa) were captured on three streptavidin-activated
flowcells of a S-CM4 sensorchip (41.2 and 44.1 RU for 6 and
15 kDa heparin respectively, and 61.9 RU for HS, a fourth one
being used as negative control surface. Using HBS-P+ running
buffer (10mM HEPES, 150mM NaCl, 0.05% surfactant P20,
pH 7.4) at a flow rate of 20 µl/min, series of 0–3,000 nM
of MASP-2 were injected over the heparin, HS and negative
control surfaces, followed by a 3min washing step with HBS-
P+ buffer to allow dissociation of the complexes formed. At
the end of each cycle, surfaces were regenerated with a 2.5min
injection of 2M NaCl. Sensorgram shown correspond to on-
line subtraction of the negative control to the heparin surface
signal. Kds were determined using the BIAcore T200 evaluation
(version 3.1) software, by steady state analysis (1:1 binding
model). For this, resonance values (Req) were taken within the
equilibrium phase (just before the end of injection) and plotted
against MASP-2 concentration. Calculated χ2 values provided
quality control of experimental data fitting. Competition assays
were performed similarly, by injecting 200 nM of MASP-2 pre-
incubated with GAGs (30µg/ml) over the heparin and negative
control surfaces. Tested GAGs included a heparin tetrasaccharide
(1HexA2S-GlCNS6S-IdoA2S-GlcNS6S) and chondroitin sulfate
A, B and C, the 15 kDa heparin being used as a positive control
(also 30µg/ml, a 10-fold excess compared to the concentration
used to load the sensor chip). Noteworthy, this experiments
was conducted using fixed tetrasaccharide and heparin mass
concentrations to reflect the fact that a 15 kDa heparin chain
comprises multiple highly sulfated tetrasaccharide (composition
of 15 kDa Heparin is provided in Seffouh et al. (42). All
experiments were independently replicated three times.
Immunohistochemistry
Four µm frozen kidney sections of five human donor kidneys
not suitable for transplantation for anatomical reasons were used
for immunofluorescent stainings. Sections were double stained
for MASP-2 in combination with the basement membrane
HS proteoglycan agrin, or in combination with HS (clone
10E4 recognizing mixed N-sulfated/N-acetylated sequences) or
triple stained with HS and activated complement factor C3
(recognizing a neoepitope on C3b, iC3b, and C3c after cleavage
of C3 by C3-convertase). Details of the immunofluorescence
procedures and the antibodies used are given in Table 1.
Photomicrographs were taken at 630x magnification with
confocal microscope (Leica SP8, Leicamicrosystems BV, Rijswijk,
the Netherlands) at the Imaging and Microscopy Center of the
University Medical Center Groningen.
RESULTS
Small Heparan Sulfate- and
Heparin-Derived Oligosaccharides
Specifically Inhibit the Lectin Pathway,
While Longer Highly Sulfated GAGs Block
All Three Routes of Complement
A library of naturally, chemically, or enzymatically modified
and synthetic GAGs, as well as size-defined HS/heparin
depolymerization products were tested for their complement
inhibiting potential in the WieLISA, which allows separate
evaluation of the three pathways of the complement system.
From the results (Table 2), it can be seen that unfractionated
heparins inhibited all three complement pathways. Heparin from
different sources e.g., porcine intestinal mucosa and bovine lung
showed strong inhibitory potential for all pathways.
Selective desulfation of heparin, either 6-O desulfation
by SULF2 (80% reduction of the 6-O content in NS2S6S
disaccharides), or by chemical N-desulfation followed by
reacetylation, resulted in some loss of complement inhibitory
potential, mostly in the classical and alternative route.
Periodate-oxidized and reduced heparin is a non-
anticoagulant heparin derivate in which the structure of
the antithrombin binding site was modified, and the results
in Table 2 show that despite losing the ability to interact with
antithrombin III, it remained able to inhibit all complement
pathways. LMW-heparins like fragmin, fraxiparin and
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TABLE 1 | Details on immunofluorescence stainings on human cryosections.
Procedure MASP-2 Agrin Heparan sulfate Activated C3
Fixation Icecold 100% aceton for
10min
Icecold 100% aceton for
10min
Icecold 100% aceton for
10min
Icecold 100% aceton for 10
min
Peroxidase inactivation 0.03% H2O2 in PBS for




1% BSA in PBS for 15min 1% BSA in PBS for 15min 1% BSA in PBS for 15min 1% BSA in PBS for 15 min





Primary antibody Rat mAb anti-human









Mouse IgG2a mouse mAb
anti-neoepitope on C3b,
iC3b and C3c, clone bH6,
1:200 (Hycult)
Secondary antibody Rabbit anti-rat IgG-HRP,
1:200 + 5% normal human
serum for (Dako, Glostrup,
Denmark)
Donkey anti-Mouse







Tertiary antibody Goat anti-rabbit IgG-HRP,
1:200 + 5% normal human
serum (Dako)
– – –










Nuclear staining Dapi for 10min Dapi for 10min Dapi for 10min Dapi for 10 min
Embedment Citifluor (Haffield PA, USA) Citifluor (Haffield PA, USA) Citifluor (Haffield PA, USA) Citifluor (Haffield PA, USA)
Stainings are performed as MASP2/agrin double staining, as MASP2/HS double staining, and as MASP2/HS/actC3 triple staining.
All antibody incubations were done for 30min at room temperature in PBS + 1% BSA. Sections were washed with PBS in between the incubation steps. Double- and triple stainings
were designed in such a way that all cross-reactions among the stainings were avoided.
enoxaparin are widely used in the clinic as anticoagulants
and showed strong potential to inhibit the three complement
pathways. N-desulfation followed by reacetylation of LMW
heparin reduced the ability to inhibit all complement pathways,
mostly the classical pathway. Size fractionation products of
limited heparinase I treated heparin showed that smaller heparin
fragments retain their ability to inhibit the LP, but were no longer
able to inhibit the CP and AP, indicating that GAG chain length
is a major determinant for CP and AP inhibition. The smallest
heparin fragment tested, i.e., tetrasaccharides (4-mer), were
found to be completely selective for inhibition of the LP.
Escherichia coli -derived K5 polysaccharides share their
polysaccharide backbone with heparin except that K5
polysaccharides carry exclusively GlcA uronic acid epimers,
while heparin features >80% IdoA C5 uronic epimers. Native
K5 does not contain any sulfate groups and did not inhibit
the complement system. O-sulfated and N + O-sulfated K5
both showed equally strong inhibitory capacity for all three
complement pathways, indicating that neither GlcA to IdoA
conversion nor N-sulfation (next to O-sulfation) is crucial for
complement inhibition, when the density of O-sulfates is high
enough (∼1,5 O-sulfates/disacch in O-sulfated K5). O-sulfated
K5 hexasaccharide did not inhibit the complement unlike
heparin hexasaccharides (see above). Whether this is due to
different positioning of the O-sulfate groups is unknown, but
suggestive, which in regular heparin is mostly IdoA2S-GlcNs6S,
and in chemically O-sulfated K5 mostly at C2 and C3 of GlcA
along with N-sulfation of Glc units.
We also tested GAGs and polysaccharides with a different
backbone structure than heparin. These results indicate that the
chemical nature of themonosaccharides and their bonds between
the monosaccharide units is of lesser importance compared to
the degree of sulfation when looking at complement inhibitory
potential. Highly sulfated polysaccharides like fucoidan and
dextran sulfate and to a lesser extent sulodexide [mixture of
heparin (80%) and dermatan sulfate (20%)] showed inhibition
of all complement pathways. Chondroitin sulfate B (dermatan
sulfate) with an intermediate amount of sulfates and high content
of iduronic acid showed some inhibition of the LP, but not of the
CP and AP, while chondroitin sulfates -A and -C and the non-
sulfated dextran T40 didn’t inhibit the three complement routes.
HS have a slightly different disaccharide composition
compared to heparin and are less and more variably sulfated (25,
44). HS from different sources (e.g., bovine kidney and porcine
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TABLE 2 | Complement inhibition by heparin(oids), (derivatives of) K5









HEPARINS AND HEPARIN DERIVATIVES
Porcine intestinal mucosa 73 (12) 97 (1) 94 (5) 2
Ovine intestinal mucosa 83 97 96 1
Bovine lung 66 90 74 1
SULF-2 treated heparin 54 96 48 1
N-desulfated, re-acetylated heparin 6 52 42 1
Periodate-oxidized and reduced
heparin
60 91 97 1
LMW-heparin (Fragmin) Mw: 6000 73 98 98 1
LMW-heparin (Fraxiparin) Mw: 4500 48 95 92 1
LMW-heparin (Enoxaparin) Mw:
4500
65 97 95 1
LMW N-desulfated, reacetylated
heparin
8 46 44 1
Heparin-derived 18-mer 13 71 20 1
Heparin-derived 16-mer 27 90 25 1
Heparin-derived 14-mer 26 92 35 1
Heparin-derived 12-mer 26 94 38 1
Heparin-derived 10-mer 14 87 21 1
Heparin-derived 8-mer 20 93 26 1
Heparin-derived 6-mer 12 93 0 1
Heparin-derived 4-mer 0 74 0 1
E. coli K5-DERIVED POLYSACCHARIDES
Native K5 0 1 3 1
O-sulfated K5 100 (0) 88 (4) 92 (3) 3
N-+ O-sulfated K5 100 93 97 1
O-sulfated K5 hexasaccharides 0 2 0 1
GLYCOSAMINOGLYCANS
Chondroitin sulfate A 3 (4) 6 (7) 8 (9)2 3
Chondroitin sulfate C 0 (0) 0 (0) 0 (0) 2
Chondroitin sulfate B (Dermatan
sulfate)
5 (7) 39 (5) 10 (10) 3
Sulodexide 52 93 73 1
POLYSACCHARIDES
Dextran T40 4 8 17 1
Dextran sulfate 100 99 100 1
Fucoidan 98 78 79 1
HEPARAN SULFATE AND HEPARAN SULFATE DERIVATIVES
HS human aorta 5 23 7 1
HS EHS mouse sarcoma 17 31 22 1
HS bovine intestine 21 76 39 1
HS bovine kidney 2 (1) 73 (0) 18 (18) 2
HS porcine mucosa 9 95 26 1
Heparan sulfate derived 18-mer 5 91 25 1
Heparan sulfate derived 16-mer 11 92 32 1
Heparan sulfate derived 14-mer 4 92 18 1
Heparan sulfate derived 12-mer 0 93 3 1
Heparan sulfate derived 10-mer 0 87 0 1
Heparan sulfate derived 8-mer 0 74 0 1
Heparan sulfate derived 4-mer 0 0 0 1
A library of GAG-derived polysaccharides was tested in the WieLISA for their complement
inhibiting potential. Values are expressed as percentage inhibition compared to control
values without inhibitor as mean ± SD or from a single experiment. GAGs were added
in a concentration of 100 ug/ml in the CP and LP assay and due to a higher serum
concentration at 200 ug/ml in the AP assay.
mucosa) showed in general substantial LP inhibition without
inhibiting the CP and AP. Smaller HS fragments were found to
be more specific inhibitors of the LP. 12-mer, 10-mer and 8-mer
HS fragments showed complete specificity for the LP and did
not show any inhibition of the CP and AP (Figures 1A,C,D).
The HS-derived 4-mer did not show any inhibitory capacity for
any pathway (HS-derived 6-mer was not available) in contrast
to heparin-derived tetrasaccharide, probably because of a lower
degree of sulfation (Table 2).
To test the effect of GAG length on the inhibitory potential
of the complement system, 5 heparin fragments ranging from
unfractionated heparin to heparin-derived tetrasaccharides were
tested in the WieLISA in a dose dependent fashion. As
expected, unfractionated heparin showed the strongest inhibition
in all pathways (Figures 1A–C). Interestingly, the LP was
inhibited most potently by unfractionated heparin with an
IC50 value of 2µg/ml in 100-times diluted serum, in contrast
to the CP (IC50: 39µg/ml) and the AP (IC50: 76µg/ml)
(Figure 1D). Heparin octasaccharides and smaller heparin
fragments become, up to the concentrations tested, specific
LP inhibitors; IC50: octasaccharides: 3µg/ml, hexasaccharides:
4µg/ml and tetrasaccharides: 21µg/ml (Figure 1D). These
results indicate that a certain heparin chain length is required for
inhibition of the CP and AP, while heparin fragments down to 4
saccharides in length can inhibit the LP.
To illustrate the effect of heparin/HS sulfation on the
inhibitory capacity of complement, we selected 6 heparin/HS/K5
preparations with different sulfation degrees from Table 1 and
displayed them in Figure 1E. Heparin with >2,5 sulfate groups
per disaccharide showed, as observed before, strong inhibitory
potential for all complement pathways. A reduced number
of sulfate groups to 1,0 or 0,8 per disaccharide, attenuated
predominantly the ability to inhibit the CP and AP. Further
lowering the sulfate content resulted in a reduced inhibition of
all complement pathways (Figure 1E).
Altogether, all three complement pathways can be blocked
by highly sulfated polysaccharides such as heparin, fucoidan,
dextran sulfate and O-sulfated K5 and to a lesser extent by some
HS preparations and dermatan sulfate. Specific complement
inhibition of the LP is achieved by some HS preparations and
small heparin- and HS-derived oligosaccharides.
Heparin Oligosaccharides Inhibit the
Proteolytic Activity of MASPs and Thereby
Reduce C4d Deposition
The previous results showed that HS/heparin-derived
oligosaccharides can specifically inhibit the LP of complement.
The LP differs from the CP only in the pattern recognition
molecule: MBL (in the WieLISA) vs. C1q, and the serine
proteases, MASP-1 and−2 vs. C1r and C1s. To pinpoint whether
the small heparin oligosaccharides interfere with MBL or
MASPs, the inhibitory effect of heparin (fragments) on the
MBL-mannan interaction was tested. Serum was co-incubated
with or without the heparin (fragments) on a mannan coated
plate and MBL binding to mannan was used as a read out. MBL
binding to mannan in the absence of inhibitors showed a dose
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FIGURE 1 | Effect of GAG length and sulfation on complement inhibition. Complement inhibitory potential of selected heparin derivatives was evaluated in a dose
dependent fashion. The concentration-response curves show that all heparin derivatives tested are strong LP inhibitors (B), while the CP and AP are only inhibited by
heparin and LMW heparin in concentrations of ≥50µg/ml (A,C). Heparin hexa-and tetrasaccharides are fully specific LP inhibitors (A–C). (D) IC50 values (µg/ml) of
the dose dependent inhibition assays (A–C) of the heparin fragments tested. (E) Illustration of the role of sulfation on complement inhibition. The average amount of
sulfate groups per disaccharide is between brackets. Heparin shows inhibitory potential for all pathways. Reducing the number of sulfate groups per disaccharide
results predominantly in a reduced potential to inhibit the CP and AP while the inhibitory potential for the LP is initially preserved. GAGs were tested at 100 (CP and LP)
or 200µg/ml (AP). Data shown are the result of a single experiment, after careful optimization of all conditions before. Heparin and HS from bovine kidney (E) as mean
+/– SEM of two independent experiments.
dependent binding, a serum concentration of 1:50 was used for
the inhibition experiments (OD: 0.96) (Figure 2A). The results
revealed that none of the selected heparin preparations, which
all inhibit the LP in the WieLISA, could inhibit the MBL binding
to mannan in any of the concentrations tested (Figure 2B). To
strengthen the conclusion that heparin did not interfere with
the MBL-mannan interaction, heparin (fragments) were tested
in a ficolin-3 mediated LP activity assay. This assay measures
LP activity with ficolin-3 as pattern recognition molecule for
immobilized acetylated BSA instead of MBL with immobilized
mannan. In ficolin-3 mediated LP activation cleaving of C4 and
C2 is, like in the MBL mediated route, dependent on MASP
activity (45). The heparin (fragments) showed a dose dependent
inhibitory pattern in the ficolin-3 mediated LP assay identical
to the MBL mediated WieLISA (Figure 2C vs. Figure 1B).
Unfractionated heparin showed the strongest inhibitory effect
with an IC50 of 3µg/ml. Decreasing the GAG length resulted in
reduced inhibitory potential for LMW heparin, octasaccharides,
hexasaccharides, and tetrasaccharides heparin (IC50: 7, 11, 16,
and 342µg/ml, respectively). Since the LP and CP differ only in
their pattern recognition molecules and their serine proteases
and we showed that the heparin (oligoaccharides) are unable to
inhibit the binding of pattern recognition molecules to pathogen
associated molecular patterns, we suggest, based on these data,
that the LP is inhibited by heparin (oligosaccharides) via the
serine proteases, the MASP enzymes.
To prove this assumpsion, we next used an assay to measure
the C4 cleavage potential (by measuring C4d deposition)
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FIGURE 2 | Heparin-derived oligosaccharides inhibit the lectin pathway of complement via inhibition of C4d deposition. To determine which LP component is inhibited
by heparin derivatives MBL and MASP inhibition were tested. Representative experiments show that MBL binds dose dependent to mannan (A). Heparin derivatives
did not inhibit the binding of MBL to mannan (B). The selected heparin fragments did however show inhibition of the LP when the LP was initiated by ficolin-3 binding
(C). Heparin fragments did also show an inhibitory effect in a C4d deposition assay, as a measure for MASP-2 activity (D). Data is expressed as a representative
measurement (A–C) or as mean ± SEM of three independent experiments (D).
of the MASPs. Since C4 is completely cleaved by MASP-2
and not by MASP-1, this is predominantly a MASP-2 assay
(46). Interestingly, unfractionated heparin showed a relatively
mild inhibitory potential (IC50: 102µg/ml) compared to the
LMW-heparin enoxaparin, heparin oligosaccharide and heparin
hexasaccharide (IC50: 63, 59, and 70µg/ml, respectively).
The weakest inhibitory effect was shown by the heparin
tetrasaccharide with an IC50 of 296µg/ml (Figure 2D). This
assay revealed that heparin oligosaccharides inhibit the LP at
the level of the MASP enzymes, most likely MASP-2, in a dose
dependent manner.
Recombinant Human MASP-2 Shows
Similar Binding Affinity for Short and Long
HS GAGs
To further strengthen the hypothesis that heparin/HS fragments
predominantly inhibit MASP-2 we performed SPR experiments
to evaluate the binding kinetics between catalytically active
recombinant human MASP-2 fragment (CCP1-CCP2-SP)
and different heparin/HS preparations. Figure 3A shows the
sensorgram of recMASP-2 binding to an immobilized 15
kDa heparin fragment. Immobilized HS (porcine mucosa)
and 6 kDa LMW-heparin showed similar sensorgrams
(Supplementary Figure 1). Interestingly the on and off rates
were very fast indicating a transient interaction, which could
indicate moderate affinity. In Figure 3B we show the fit of the
experimental data for the binding of MASP-2 to 15 kDa heparin
upon representative steady-state analysis. Calculations of the
affinity indeed show Kd values between 1.5 and 2.0µM for
the heparins and HS tested (Figure 3C). The observation that
MASP-2 showed similar affinity for the 6 kDa heparin and the 15
kDa heparin and HS (usually between 12 and 20 kDa) indicates
that MASP-2 recognizes a rather short and comparable motif on
heparin/HS. Using the 15 kDa heparin as a scaffold for MASP-
2, competition assays were performed using unfractionated
heparin, heparin-derived tetrasaccharide (identical composition
as Org 32102, namely 1HexA2S-GlCNS6S-IdoA2S-GlCNS6S)
and chondroitin A, B, and C as competitors. Results show
that the heparin-derived tetrasaccharide reduced the binding
of MASP-2 to 15 kDa heparin by ±40%. Although further
experiments (including direct MASP-2/tetrasaccharide binding
analysis) would be needed to ascertain that a tetrasaccharide is
the actual minimal size required for MASP-2 binding, these data
again suggest that MASP-2 is recognized by a short heparin/HS
motif (Figure 3D).
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FIGURE 3 | The recombinant catalytic CCP1-CCP2-SP domain of MASP-2 shows equal affinity for heparan sulfate, small, and larger heparin preparations. (A)
Surface plasmon resonance sensorgram of binding of a (from clear to dark lines) 0–3,000 nM concentration range of recombinant MASP-2 to 15 kDa heparin,
showing rapid on and off rates, indicating a transient interaction. Binding of MASP-2 to HS and 6 kDa heparin produced similar graphs (Supplementary Figure 1).
(B) Representative steady-state analysis and fit of the experimental data for the binding of MASP-2 to 15 kDa heparin. (C) Affinity calculations reveal micro molar
affinity for MASP-2 binding to HS, 6 kDa, and 15 kDa heparin. (D) Competition experiments using a tetrasaccharide (4-mer) heparin fragment results in a 40%
reduction of the binding of MASP-2 to immobilized 15 kDa heparin, while chondroitin sulfates fail to inhibit the MASP-2/heparin interaction. Experiments were
expressed as mean ± SEM from three independent experiments.
Sulfation Pattern Determines the
MASP-2-Mediated Lectin Pathway
Inhibitory Potential of Tetrasaccharides
To determine the importance of sulfate group positioning within
tetrasaccharides for the inhibition of the LP, various heparin-
derived tetrasaccharides obtained after limited heparinase I
digestion as well as a set of synthetic tetrasaccharides were tested
in the WieLISA and the C4 activation assay (37). As a reference
the heparin tetrasaccharide Org 32102 (>90% 1UA2S-GlcNS6S-
IdoA2S-GlcNS6S as evaluated by NMR) and unfractionated
heparin used in the experiments above were added. The
tetrasaccharides were tested in both the WieLISA and MASP-
2-mediated C4 deposition assay. None of the tetrasaccharides
affected the CP and the AP (data not shown). As shown before,
results in the LPWieLISA and theMASP-mediated C4 deposition
assay showed comparable results (Table 3 and Figure 4).
Strongest inhibition in both assays was obtained by the fully
hexasulfated 1UA2S-GlcNS6S-IdoA2S-GlcNS6S (Org 32102)
tetrasaccharide. The hexasulfated preparations with the 1UA2S
at the non-reducing end (by heparinase I elimination reaction),
like Org32102 and SAGAG peak 3, showed better inhibitory
capacity compared to the synthetic variant, tetrasaccharide T40.
Pentasulfated tetrasaccharides also showed inhibitory capacity
in both assays, although to a lesser extent compared to the
hexasulfated tetrasaccharide. Thus, SAGAG Peak 1 and 2 (having
5 sulfate groups) vs. SAGAG peak 3 (six sulfate groups), and
synthetic tetrasaccharide T38 (having 5 sulfate groups) vs. T40
(having 6 sulfate groups). The data indicate that one of the 2-O
or 6-O sulfates within the tetrasaccharide can be missed, leaving
a pentasulfated HS/heparin tetrasaccharide being the minimal
MASP-2 binding sequence in HS and heparin. Further reduction
in sulfation to four or less sulfate groups/tetrasaccharide led
to loss of all inhibitory potential in both the LP Wielisa and
the MASP-2 C4 deposition assay (Table 3). Not tested in these
experiments are the influence of 3-O sulfation and the eventual
effect of GlcNAc or GlcNH+3 modifications.
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TABLE 3 | Inhibitory capacity of heparin-derived and synthetic tetrasaccharides in the Lectin Pathway WieLISA and MASP-mediated C4 deposition assay.
Tetrasaccharide Structure Inhibition (%) in WieLISA Repeats Inhibition (%) in C4 assay Repeats
BY HEPARINASE I TREATMENT OF (LMW-) HEPARIN
Org 32102 1UA2S-GlcNS6S-IdoA2S-GlcNS2S (90%)a 76 (2) 3 61 (6) 3





SAGAG Peak 1 1UA2S-GlcNS6S + 1UA2S-GlcNSc 46 1 55 1
SAGAG Peak 2 1UA2S-GlcNS6S + 1UA-GlcNS6Sc 28 1 47 1
SAGAG Peak 3 1UA2S-GlcNS6S + 1UA2S-GlcNS6Sc 68 1 66 1
SYNTHETIC TETRASACCHARIDES
T7 IdoA-GlcNAc6S-IdoA-GlcNAc6S-(CH2)5NH2 0 1 0 (0) 3
T11 IdoA-GlcNAc6S-IdoA2S-GlcNAc6S-(CH2)5NH2 0 1 0 (0) 3
T13 IdoA-GlcNS6S-IdoA-GlcNS6S-(CH2)5NH2 0 1 0 (0) 3
T38 IdoA-GlcNS6S-IdoA2S-GlcNS6S-(CH2)5NH2 24 1 10 (10) 3
T39 IdoA2S-GlcNAc6S-IdoA2S-GlcNAc6S-(CH2)5NH2 0 1 0 (0) 3
T40 IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-(CH2)5NH2 30 1 16 (3) 3
Values are expressed as percentage inhibition compared to control values without inhibitor expressed as mean ± SD or from a single experiment. GAGs were added in a concentration
of 100 ug/ml in the LP and C4 assay.
aComposition and purity by NMR spectroscopy.
bComposition by NMR spectroscopy.
cComposition after digestion of the tetrasaccharide with a cocktail of heparinase I, II, and III followed by RPIP-HPLC disaccharide identification.
MBL-MASP Complex Binds to Immobilized
Heparin and Tissue Heparan Sulfate
We have shown in this study that specific domains in heparins
and HS can inhibit the LP of complement by inhibiting the
enzymatic activity of the MASP2 enzyme. To test whether the
MASP-2 in serum indeed binds to solid phase heparin/HS, we
incubated serum in heparin-albumin coated wells and measured
whether MASP-2 was bound to the immobilized heparin. Results
showed binding of serum-derived MASP-2 to immobilized
heparin in a dose dependent fashion (Figure 5A), indicating
that serum MASP-2 could bind to HS/heparin on cells and
tissues. RecMASP-2 showed binding to heparin albumin as well
(Figure 5B).
We thus hypothesized that HS in extracellular matrices
and cell membranes could function as docking platforms for
MASP-2 in vivo. To test this hypothesis we double stained
human donor kidneys for MASP-2 and basement membrane
HS proteoglycan agrin, which is localized in renal glomerular,
tubular and vascular basement membranes. We also performed
a double staining for MASP-2 and HS (mAb 10E4). Both
double stainings revealed MASP-2 to be present in a subset
of tubular basement membranes, partly colocalizing with agrin
and HS (Figures 5C–H, 6A–C). The fact that not all basement
membranes showed MASP-2 positivity might be because MASP-
2 is just very locally produced and stored in the underneath
basement membrane, and/or that just a small subset of
renal basement membranes displayed HS with a MASP-2
binding motif.
However, from these data it is not clear whether MASP-2
is enzymatically active or not when co-localized to basement
membrane HSPGs. Therefore, we performed a triple staining
for HS using mAb 10E4, MASP-2 and C3b, the cleaved product
of C3, also called active C3. Although the 10E4 and MASP-2
epitopes of HS are different from each other, in Figures 6D–G
it can be appreciated that MASP-2 and HS showed partial co
localization in some basement membranes of vascular structures
and in Bowman’s capsule. Cleaved C3 within the glomerulus did
not colocalize with MASP-2 and/or HS. It can also be seen that
cleaved C3 occasionally showed co localization with MASP-2,
but not when MASP-2 is co localized with 10E4/HS. Within the
limitations of this approach, we speculate that MASP-2 bound
to tissue HS is not able to activate the LP and thus no C3b can
be formed i.e., MASP-2 might be enzymatically inhibited by the
binding to HSPGs.
DISCUSSION
The interaction of GAGs (especially heparin-related GAGs) with
complement has been known for some decades, but it has never
been tested on a larger scale whether GAGs and derivatives
thereof could be specific inhibitors of either of the complement
pathways. In this study we tested a library of GAG-related
polysaccharides for their complement inhibitory capacity and
showed that the LP of complement can be specifically blocked
by some HS and heparin- and HS-derived oligosaccharides.
Decreasing the disaccharide length of the HS and heparin
oligosaccharides resulted in more specificity for the LP and loss
of CP and AP inhibitory activity. Since the LP shares the C3
convertase C4b2a with the CP, LP-specific GAGs must inhibit
either the MASP enzymes or the pattern recognition molecules
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FIGURE 4 | Inhibition of the lectin pathway by tetrasaccharides requires at least pentasulfation. Using synthetic tetrasaccharides (A,C) and purified tetrasaccharides
(B,D), we determined that LP inhibition requires at least a pentasulfated tetrasaccharide. All penta- and hexa-sulfated oligosaccharides showed inhibition in both the
LP WieLISA and the C4 activation test. Removing both IdoA2S sulfate groups or both N-sulfate groups resulted in vanishing of the inhibitory potential. Displacement
of an iduronic acid by an unsaturated uronic or hexuronic acid results in an improvement of inhibitory potential in both assays. For data on the sulfation degree of the
tetrasaccharides see Table 3. As a reference the non-synthetic heparin tetrasaccharide 32102 and unfractionated heparin, used in the former experiments, was
added to experiment (A,C). Data is expressed as representative measurement (A,B,D) or as the mean ± SEM of three independent experiments (C).
of the LP. Our results show that heparin fragments inhibited the
cleaving of C4, but did not affect the binding of MBL to mannan,
suggesting a blocking effect of GAGs on eitherMASP-1 orMASP-
2 activity. This conclusion is further strengthened by the finding
that the tested GAGs are also able to inhibit the LP initiated
by ficolin-3 as a pattern recognition molecule. We could also
show binding of serum-derived MASP-2 as well as recMASP-2
to immobilized heparin and demonstrated the binding affinity of
recombinant MASP-2 to heparins and HS. Moreover, partial co-
localization was seen of MASP-2 and agrin/10E4 HS epitope in
some basementmembrane of tubuli and vessels in human kidney,
while activated C3 did not co-localize. These data might suggest
that HS in situmight function as a docking platform for MASP-2
rendering the enzyme inactive, thereby eventually protecting the
tissue from LP complement activation.
GAG length, disaccharide backbone composition, and
sulfation pattern form the main determinants for protein
binding properties of GAGs in general and this study shows that
this holds true for complement components as well. Although
the heparin/HS (oligosaccharides) were tested in a fixed µg/ml
concentration, increasing the difficulty to directly compare small
and large fractions, it can be appreciated that in larger GAGs, the
complement inhibitory capacity is predominantly determined
by sulfation degree and less by disaccharide composition and
linkages. GAGs carrying a different backbone compared to
heparin like O-sulfated E. coli K5 polysaccharide, and GAG-like
polysaccharides fucoidan and dextran sulfate show equally
strong inhibition of all complement pathways, stressing the
role of GAG sulfation in complement inhibition. It can be
appreciated from Table 2 that in most cases the inhibitory
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FIGURE 5 | HSPG’s might serve as a docking platform for the MBL/MASP complex. (A) Incubation of serum on a heparin-albumin coated plate results in binding of
MASP-2 to the heparin. (B) recMASP-2 binds to heparin-albumin coated on a plate. (C–H) Confocal immunofluorescence double staining of human donor kidneys for
MASP-2 (red) and agrin (green) showed partial co localization in the basement membranes of some tubuli, within Bowman’s capsule and some blood/lymph vessel
basement membranes. Data is expressed as representative measurement (A) or as mean ± SEM of two independent experiments (B). Scale bars indicate 50µm.
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FIGURE 6 | MASP2 is bound to HSPGs in an enzymatically inactive state. (A–C) Confocal immunofluorescence double staining of HS marker 10E4 (green) showed
partial co localization with MASP-2 (red) in some tubular and vascular basement membranes of human donor kidneys. (D–G) Confocal immunofluorescence triple
staining for HS mAb 10E4 (green), MASP-2 (red) and cleaved C3 (white). MASP-2 colocalized partially with HS in some vascular basement membranes and Bowmans
capsule, but not with activated C3. Activated C3 is predominantly localized in the glomerulus (single positive) and not seen where MASP-2 co localizes with 10E4,
indicating that MASP2 is bound the HSPGs in an inactive state. Scale bars indicate 50µm.
capacity of GAGs is comparable for the CP and AP. This might
suggest that the CP and AP share an inhibitory GAG binding
protein and that the GAG binding site in the LP is unique within
the complement system. The known interactions between GAGs
and the complement system have been summarized by us before
(47) and we have more extensively investigated the interaction
between GAGs and properdin (12). Interestingly, the GAGs
showing the highest affinity for properdin in the study conducted
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earlier also show the strongest CP and AP inhibition (12). This
might indicate a role for the GAG/properdin interaction in our
current results. Properdin is a stimulator of the AP, by stabilizing
the C3 convertase, but can have the same effect in the CP since
cleaving of C3 by the C3 convertase C4bC2a can be followed by
AP activation.Whether the inhibition by GAGs of the CP and AP
is indeed properdin mediated or not should be studied further,
since interactions between GAGs on one hand and AP activator
properdin, AP inhibitor factor H (13) and CP inhibitors like
C1-inhibitor on the other hand have been described Caughman
et al. (48).
This study showed that smaller heparin and HS
depolymerization products lose their ability to inhibit the
CP and AP and become specific inhibitors for the LP. HS
oligosaccharides start to be LP specific from dp12 and heparin
from dp6. Our surface plasmon resonance experiments indicated
that MASP-2 recognizes a small GAG epitope. Of note, heparin is
significantly more sulfated than HS (∼2.5 and ∼0.85 sulfates per
disaccharide, respectively). Furthermore, HS oligosaccharides
were generated using heparinase III, which specificity for
(GlcNAc ± 6S–GlcA) disaccharides will produce fragments with
low/non-sulfated saccharide extremities. We therefore assume
that larger (dp6–dp12) HS oligosaccharides may contain just
one MASP2 binding site connected to low sulfated, biologically
inactive HS stretches. Whereas, larger (dp6–dp12) heparin
oligo’s, due to high sulfation, also start to recognize C1inh,
ATIII and other members of the complement serine proteases
and therefore start to inhibit the CP and AP besides the LP.
The smallest component capable of inhibiting the LP is a
tetrasaccharide, which needs to have at least pentasulfation
to show inhibitory function. This is interesting because other
GAG/protein interactions e.g., heparin and ATIII have shown to
require larger high sulfation stretches. Therefore, the interaction
of a tetrasaccharide with MASP enzymes holds clinical potential.
Interestingly, replacing the iduronic acid at the non-reducing end
of the tetrasaccharide by unsaturated 1HexA could increase the
inhibitory potential, suggesting the importance of the backbone
structure. Alternatively, the reducing terminal—(CH2)5NH2
derivatization of the synthetic tetrasaccharides might interfere
the interaction with MASP-2 to some extent.
We showed in this study that the inhibitory effect of GAGs
on the lectin route of complement is not pattern recognition
molecule related, but rather MASP related. As elegantly shown
by Héja and colleagues, MASP-2 is solely responsible for the
activation of C4 and both MASP-1 and 2 are responsible for
the activation of C2 (46). This study shows that GAGs inhibit
the C4 activation and that GAGs show interaction with the
catalytic domain of MASP-2. Therefore, we can conclude that
GAGs interact with MASP-2 and inhibit the enzymatic activity.
Literature has demonstrated that MASP-2, but not MASP-1,
has a highly positively charged exosite located in the serine
protease domain, which differs from de described exosite in C1s
(49, 50). Under physiological conditions, this positively charged
exosite is believed to be the binding site of C4. C4 carries a
negatively charged cluster consisting of three tyrosine-sulfate
residues, interaction of these tyrosine-sulfate residues with the
positively charged exosite on MASP-2 and C1s is crucial for
cleaving, and therefore activity, of C4 (51, 52). Since heparin, and
HS to a lesser extent, is negatively charged due to their sulfate
groups, we propose that specific LP inhibition by HS and heparin
oligosaccharides occurs via binding to this positively charged
exosite. In Figure 7, we aligned the amino acid sequence of the
serine protease domains of MASP-2, MASP-1, and C1s. In green
we indicated the positively charged arginine and lysine residues
in MASP-2 involved in the recognition of the tyrosine-sulfate
residues in C4 (K450, K503, R578, and R583). In red we showed
them in C1s (K575, R576, R581, and K583). As can be seen,
such an exosite is lacking in MASP-1. Moreover, MASP-1 is not
cleaving C4, just C2. Moreover, because we found the inhibition
of the C4 deposition assay we studied MASP-2 and not MASP-
1. Therefore, these data strongly suggest that the heparin oligo’s
block the interaction ofMASP-2/C4 interaction at the interface of
the MASP-2 exosite with the tyrosin-sulfate residues of C4, and
thereby prevents cleavage of C4.
It has been described that protease inhibitors like C1inh,
ATIII, and tissue factor pathway inhibitor can form complexes
with the MASP proteases (15, 54) and could therefore influence
our results by heparin mediated activation of these serine
protease inhibitors followed by inactivation of the MASP
enzymes by proteolytic cleavage. We deem it however unlikely
since ATIII needs minimally a 3-O sulfated pentasaccharide
which is not present in the synthetic tetrasaccharides tested
(25). C1inh and TFPI are also not very likely involved, since
according to literature both protease inhibitors show an increased
protease activity at low heparin concentrations and blocking of
the protease activity at high heparin concentrations (15, 55).
We never observed such kinetics using the WIELISA or C4
deposition assays. Besides, the 1M NaCl conditions in the C4
deposition assay the MASPs will not react with the serpins.
This study shows that the serum-derived MASP-2 can bind
to heparin and HS GAGs and inhibit the LP of complement.
These findings suggest that HS proteoglycans in vivo can act
as a docking station for MASP-2 and preclude LP activity. In
support to this, we found some co-localization of MASP-2 and
HS proteoglycan agrin and HS in Bowman’s capsule and the
basement membranes of some tubuli and vessels. We were not
able to show cleaved C3 to co-localize with HS and MASP-
2. To test HS-dependent MASP-2 binding renal sections were
pretreated with heparitinase. Effective enzymatic cleavage of
HS was shown by induced staining using anti-1HS stub mAb
3G10, which after heparitinase became brilliant positive in all
extracellular matrices of the kidney. Nevertheless, the intensity
of the MASP-2 staining did not diminish after heparitinase (data
not shown). This could mean that MASP-2 is not physically
bound with HS. However, we cannot exclude that its binding
to HS precludes the heparitinase enzyme to cleave HS. Another
explanation could be that the MASP-2 in renal tissue is part
of a larger complement complex, including MASP-1, MBL, and
eventually other complement factors (C2 and C4 eg). These other
complement factors also might interact with renal determinants,
other than HS. This means that digestion of HS will not reduce
MASP-2 presence. All in all, such an enzymatic approach is not
conclusive. Although our immunofluorescence data is far from
robust proof, this might suggest that MASP-2 is stored inactively
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FIGURE 7 | Amino acid sequence alignment of the serine protease domains of MASP-2, C1s and MASP-1. Sequence alignment was done by Clustal W (https://
www.genome.jp/tools-bin/clustalw) as described by Thompson et al. (53). Amino acid sequences were obtained in Uniprot (https://www.uniprot.org/). Indicated in
green are the positively charged arginine and lysine residues in MASP-2 involved in the recognition of the tyrosine-sulfate residues in C4 (K450, K503, R578, and
R583). In red these residues are shown in C1s (K575, R576, R581, and K583). As can be seen, the positively charged exocites of MASP-2 and C1s clearly differs
from each other, while such a positively charged exosite is lacking in MASP-1.
in the basement membrane and we speculate that it might be
released upon the right stimuli e.g., by the action of heparanase
or oxidative stress.
We show in this study that HS and small heparin fragments
are specific LP inhibitors, although the interaction is in the
micromolar affinity range resulting in rather high IC50 values.
To date there is no specific LP inhibitor clinically available,
although a phase II clinical trial in renal patients using
humanized anti-MASP-2 mAb (OMS721 by OMEROS, Saettle
WA, USA) was recently closed with promising results in
patients suffering from IgA nephropathy and lupus nephritis.
Furthermore, an interesting study was recently published
introducing a modified TFPI 1 domain as a potential MASP-
2 inhibitor (56). Current treatment option for LP mediated
conditions would be C5 inhibitor eculizumab. However,
eculizumab is very expensive and inhibits all three complement
pathways. The use of polysaccharide-based therapeutics has
the advantages: production can be cheap and easy, and
polysaccharides are not susceptible to proteolytic enzymes,
making them less vulnerable to degradation. Moreover, decades
of experience has been obtained with heparin based therapeutics
in the field of anti-coagulation. Therefore, we believe that
polysaccharide based specific LP inhibitors have good potential
for further development. The comparison of four different
β-elimination heparin-derived tetrasaccharide fragments and
synthetic tetrasaccharides revealed the best LP/MASP inhibition
by the fully hexasulfated 1HexA, 2S-GlcNS, 6S-1HexA,2S-
GlcNS, 6S structure. This structure could be a promising starting
molecule to develop related small glycan-based LP/MASP
inhibitors with higher affinity.
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